DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH THE UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES

NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with The Uniformed Services University of the Health Sciences (“USU”), an institution of higher learning within the United States Department of Defense (DoD), and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) on behalf of USU’s Battlefield Shock and Organ Support Research Program (BSOS). The partnership includes researching the effectiveness of Daxor’s BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury.

“Diagnostics currently used to guide battlefield resuscitation and transfusions, such as heart rate, cardiac output, stroke volume, and blood pressure, often misdiagnose the severity of volume derangement,” said Michael Feldschuh, CEO and President of Daxor. “Daxor’s BVA-100 Blood Volume Analysis (BVA) technology can greatly improve the existing standard of care by ensuring treatment decisions based on precise measurement of blood volume for better trauma survival outcomes.”

Extensive peer-reviewed medical literature has validated Daxor’s BVA's enhancement of interventions through reliable and accurate blood volume measurement. Most relevant to military medicine is a prospective randomized controlled trial which demonstrated that, compared to standard care, actionable BVA-100 information changed surgical intensive care unit (SICU) fluid and red blood cell interventions by 44% of cases while reducing patient mortality by 66%. Additionally, it cut patients’ length of stay and days on a ventilator.

The collaboration will encompass multiple projects with the ultimate objective of saving the lives of American soldiers and translating the results to civilian care. Target indications include hemorrhage, burn, trauma, sepsis and acute respiratory distress syndrome.

“Collaborating with USU and HJF is an important milestone as we have been working on new technology and filed patent applications to extend the capabilities of our current FDA-cleared diagnostic system, the BVA-100, for both civilian and military use,” said Jonathan Feldschuh, Chief Scientific Officer at Daxor. “The results of this work will also support work on the next generation BVA device currently in development under a separate contract with the Department of Defense.”